Trait Name |
Trait Full Name |
Panel |
Author |
Year |
Cases* |
Controls |
TAG Set Threshold |
CSEA p (chi2) |
Cross Disorder Brain | Cross Disorder Brain | MTC | PGC | 2013 | 33332 | 27888 | 1.00e-4 | 4.41e-2 |
Fasting Proinsulin | Fasting Proinsulin | MTC | Strawbridge | 2011 | NA | 16378 | 1.00e-2 | 3.94e-2 |
Gout | Gout | MTC | Kottgen | 2013 | 2115 | 67259 | 1.00e-2 | 2.37e-3 |
Gout | Gout | MTC | Kottgen | 2013 | 2115 | 67259 | 1.00e-3 | 3.57e-2 |
MDD | Major Depressive Disorder | MTC | McMahon | 2010 | 6686 | 9068 | 1.00e-2 | 2.25e-2 |
MDD | Major Depressive Disorder | ETC | Wray | 2018 | 16823 | 25632 | 1.00e-5 | 3.39e-2 |
Primary Sclerosing Cholangitis | Primary Sclerosing Cholangitis | MTC | Ji | 2017 | 2871 | 12019 | 5.00e-2 | 4.99e-2 |
Tiredness | Tiredness | MTC | Deary | 2018 | NA | 108976 | 1.00e-3 | 3.10e-2 |
Albuminuria | Urinary Albumin to Creatinine Ratio | MTC | Teumer | 2016 | NA | 54450 | 1.00e-3 | 4.36e-2 |
Alcohol Consumption | Alcohol Consumption All Dichotomous | MTC | Schumann | 2016 | NA | 74711 | 1.00e-2 | 3.33e-2 |
Anthropometrics Sex Stratified | Hip Circumference Women | MTC | Randall | 2013 | NA | 43316 | 1.00e-2 | 1.15e-2 |
Aortic Valve Calcification | Aortic Valve Calcification | MTC | Thanassoulis | 2013 | NA | 6942 | 1.00e-2 | 1.36e-2 |
Bone Mineral Density Lifecourse | Total Body Bone Mineral Density 45 to 60 | MTC | Medina-Gomez | 2018 | NA | 18805 | 5.00e-2 | 4.63e-2 |
Bone Mineral Density | Lumbar Spine Bone Mineral Density | MTC | Zheng | 2015 | NA | 23699 | 1.00e-2 | 4.96e-2 |
Ectopic Fat Traits | Visceral Adipose Tissue Volume All | MTC | Chu | 2017 | NA | 14863 | 1.00e-2 | 3.76e-3 |
Facial Shape | Mod10 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 4.31e-2 |
Facial Shape | Mod12 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 4.11e-2 |
Facial Shape | Mod15 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.80e-3 |
Facial Shape | Mod20 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 2.27e-2 |
Facial Shape | Mod24 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 2.93e-2 |
Facial Shape | Mod4 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 4.34e-2 |
Facial Shape | Mod40 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 1.21e-2 |
Facial Shape | Mod45 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 3.26e-2 |
Facial Shape | Mod46 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 2.93e-2 |
Facial Shape | Mod51 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 3.35e-2 |
Glucose Stimulated Insulin Secretion | Insulin Response At 30 Minutes Corrected For BMI | MTC | Prokopenko | 2014 | NA | 10837 | 1.00e-3 | 1.58e-2 |
Ischaemic Stroke | Cardioembolic Stroke | MTC | Traylor | 2012 | 1715 | 12285 | 5.00e-2 | 8.08e-3 |
Ischaemic Stroke | Cardioembolic Stroke | MTC | Traylor | 2012 | 1715 | 12285 | 1.00e-2 | 3.19e-2 |
Ischaemic Stroke | Small Vessel Disease | MTC | Traylor | 2012 | 2275 | 12285 | 5.00e-2 | 3.32e-2 |
Ischaemic Stroke | Small Vessel Disease | MTC | Traylor | 2012 | 2275 | 12285 | 1.00e-3 | 2.57e-2 |
Kidney Function | Chronic Kidney Disease | MTC | Kottgen | 2010 | NA | 67093 | 1.00e-2 | 2.22e-2 |
Reproductive Behavior | Age First Birth Female | MTC | Barban | 2016 | NA | 189656 | 5.00e-2 | 1.85e-2 |
Sleep Duration | Undersleeper | MTC | Jones | 2016 | NA | 110188 | 5.00e-2 | 1.78e-2 |
Sleep Duration | Average Sleep Duration | MTC | Jones | 2016 | NA | 127573 | 1.00e-2 | 2.68e-3 |
Smoking | Log Age Onset Smoking | MTC | Furberg | 2010 | NA | 22438 | 5.00e-2 | 6.31e-3 |
AUD | Alcohol Dependency | ETC | Walters | 2018 | 11569 | 34999 | 1.00e-2 | 2.58e-2 |
Active | Time to most active 10 hours | ETC | Jones | 2019 | NA | 85670 | 5.00e-2 | 3.51e-2 |
Sleep | Sleep duration variability | ETC | Jones | 2019 | NA | 84810 | 5.00e-2 | 1.03e-2 |
Sleep | Sleep duration variability | ETC | Jones | 2019 | NA | 84810 | 1.00e-2 | 3.31e-3 |
Sleep | Sleep duration variability | ETC | Jones | 2019 | NA | 84810 | 1.00e-3 | 5.03e-3 |
Sleep | Sleep time to midpoint | ETC | Jones | 2019 | NA | 84810 | 1.00e-3 | 9.55e-3 |
Facial attractiveness | Facial attractiveness, male raters | ETC | Hu | 2019 | NA | 3928 | 5.00e-2 | 2.75e-2 |
Facial attractiveness | Facial attractiveness, female raters | ETC | Hu | 2019 | NA | 3928 | 1.00e-2 | 2.56e-2 |
Chronotype | Chronotype | ETC | Jones | 2019 | NA | 449734 | 1.00e-2 | 4.78e-2 |
BMI | Normal body mass index vs thin control, adult vs thin adult | ETC | McKay | 2019 | 6460 | 1471 | 1.00e-3 | 4.77e-2 |
Osteoarthritis | Knee osteoarthritis | ETC | Tachmazidou | 2019 | 24955 | 376169 | 1.00e-2 | 1.54e-2 |
Alcohol consumption | Alcohol consumption, drinks-per-week | ETC | Liua | 2019 | NA | 941280 | 1.00e-2 | 4.68e-3 |
Alcohol consumption | Alcohol consumption, drinks-per-week | ETC | Liua | 2019 | NA | 941280 | 1.00e-3 | 1.88e-2 |
Alcohol consumption | Alcohol consumption, drinks-per-week | ETC | Liua | 2019 | NA | 941280 | 1.00e-4 | 6.55e-3 |
Alcohol consumption | Alcohol consumption, drinks-per-week | ETC | Liua | 2019 | NA | 941280 | 1.00e-5 | 4.05e-2 |
Smoking | Smoking cessation | ETC | Liua | 2019 | NA | 547219 | 1.00e-2 | 1.13e-2 |
Smoking | Smoking cessation | ETC | Liua | 2019 | NA | 547219 | 1.00e-5 | 3.14e-2 |
Sleep | Sleep duration | ETC | Doherty | 2018 | NA | 91105 | 1.00e-4 | 4.07e-2 |
Hippocampal volume | Hippocampal tail volume, corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-2 | 4.57e-2 |
Brain volume | Dentate gyrus granule cell layer volume corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-3 | 4.89e-2 |
Hippocampal volume | Hippocampal subfield CA4 volume, corrected for total hippocampal volume | ETC | Meer | 2018 | NA | 21297 | 1.00e-2 | 4.80e-2 |
Medication use | Medication use (antihistamines for systemic use) | ETC | Wu Y | 2019 | 13,984 | 137,652 | 1.00e-2 | 9.05e-3 |
Medication use | Medication use (antihistamines for systemic use) | ETC | Wu Y | 2019 | 13,984 | 137,652 | 1.00e-3 | 1.31e-2 |
Medication use | Medication use (antiglaucoma preparations and miotics) | ETC | Wu Y | 2019 | 5,215 | 95,653 | 1.00e-3 | 8.84e-3 |
Periodontal disease | Periodontal disease related phenotype (PCT4) | ETC | Offenbacher S | 2016 | NA | 975 | 5.00e-2 | 4.76e-2 |
Periodontal disease | Periodontal disease related phenotype (PCT6) | ETC | Offenbacher S | 2016 | NA | 975 | 1.00e-2 | 3.28e-2 |
Nonalcoholic Liver disease | Nonalcoholic fatty liver disease | ETC | Namjou B | 2019 | 1,106 | 8,571 | 5.00e-2 | 3.24e-2 |
Autistic traits score | Autistic traits score (Social and Communication Disorders Checklist) | ETC | Massrali A | 2019 | NA | 5,628 | 1.00e-2 | 4.11e-2 |
Temporal lobe volume | Temporal lobe volume | ETC | van der Lee SJ | 2019 | NA | 15,269 | 5.00e-2 | 1.12e-2 |
Birth | Gestational age at birth (child effect) | ETC | Liu X | 2019 | NA | 84,689 | 1.00e-3 | 1.66e-2 |
Birth | Early spontaneous preterm birth | ETC | Liu X | 2019 | 1,139 | 60,148 | 5.00e-2 | 1.72e-2 |
Alcohol consumption | Alcohol consumption | ETC | Evangelou E | 2019 | NA | 480,842 | 1.00e-4 | 4.04e-2 |
Alcohol consumption | Alcohol consumption | ETC | Evangelou E | 2019 | NA | 480,842 | 1.00e-5 | 3.53e-2 |
Asthma | Asthma (adult onset) | ETC | Zhu Z | 2019 | 22,296 | 347,481 | 1.00e-2 | 1.46e-2 |
Lung function | Lung function (FEV1) variance | ETC | Wang H | 2019 | NA | 317,285 | 5.00e-2 | 2.59e-2 |
Macular degeneration | Disease progression in age-related macular degeneration (adjusted for baseline) | ETC | Yan Q | 2018 | NA | 2,721 | 1.00e-3 | 3.39e-2 |
Uterine fibroids and heavy menstrual bleeding | Uterine fibroids and heavy menstrual bleeding | ETC | Gallagher CS | 2019 | 3,409 | 199,171 | 1.00e-3 | 4.77e-2 |
Uterine fibroids | Uterine fibroids | ETC | Gallagher CS | 2019 | 20,406 | 223,918 | 5.00e-2 | 1.41e-3 |
Uterine fibroids | Uterine fibroids | ETC | Gallagher CS | 2019 | 20,406 | 223,918 | 1.00e-4 | 1.16e-2 |
Optic disc area | Optic disc area | ETC | Bonnemaijer PWM | 2019 | NA | 24,509 | 1.00e-2 | 2.72e-2 |
Optic disc area | Optic disc area | ETC | Bonnemaijer PWM | 2019 | NA | 24,509 | 1.00e-4 | 3.74e-2 |
Optic disc area | Optic disc area | ETC | Bonnemaijer PWM | 2019 | NA | 24,509 | 1.00e-5 | 1.55e-2 |
Vertical cup to disc ratio | Vertical cup-disc ratio | ETC | Bonnemaijer PWM | 2019 | NA | 25,180 | 5.00e-2 | 9.02e-3 |
Vertical cup to disc ratio | Vertical cup-disc ratio | ETC | Bonnemaijer PWM | 2019 | NA | 25,180 | 1.00e-2 | 9.09e-3 |
Vertical cup to disc ratio | Vertical cup-disc ratio | ETC | Bonnemaijer PWM | 2019 | NA | 25,180 | 1.00e-3 | 2.27e-2 |
Vertical cup to disc ratio | Vertical cup-disc ratio | ETC | Bonnemaijer PWM | 2019 | NA | 25,180 | 1.00e-5 | 3.95e-2 |
Refractive error | Refractive error (age-at-onset of spectacle wearing-inferred) | ETC | Ghorbani Mojarrad N | 2020 | NA | 287,448 | 1.00e-3 | 2.50e-2 |
Refractive error | Refractive error (age-at-onset of spectacle wearing-inferred) | ETC | Ghorbani Mojarrad N | 2020 | NA | 287,448 | 1.00e-4 | 2.55e-2 |
CCL24 | CCL24 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 3.69e-2 |
Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 5.00e-2 | 4.17e-2 |
Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 1.00e-2 | 2.64e-2 |
Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 1.00e-3 | 1.79e-2 |
Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 1.00e-4 | 1.89e-3 |
Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 1.00e-5 | 2.18e-3 |
Retinal detachment | Retinal detachment or retinal break | ETC | Boutin TS | 2020 | 6148 | 59546 | 1.00e-4 | 3.21e-2 |
* If the number of cases is 0/NA, it means the phenotype is a continuous data type and the number of controls is the total number of samples.